Rare Genetic Diseases

Resource Center

News
Research Summaries
Resources
FDA Alerts Pearls of Wisdom From the Journal
Insights
Commentary Podcasts Q&As Videos
Interactive
Polls Quizzes Slideshows
Events & Education

FDA Alerts

FDA Alert
fda
FDA Alert
FDA Approves First Prescription Nasal Spray to Reverse Opioid Overdose
05/27/2023
Jessica Ganga
The FDA’s approval of nalmefene hydrochloride nasal spray marks the first of its kind for health care and community use.
05/27/2023
FDA Alert
fda
FDA Alert
FDA Approves First Prescription Nasal Spray to Reverse Opioid Overdose
05/27/2023
Jessica Ganga
The FDA’s approval of nalmefene hydrochloride nasal spray marks the first of its kind for health care and community use.
05/27/2023
FDA Alert
fda
FDA Alert
FDA Approves First Prescription Nasal Spray to Reverse Opioid Overdose
05/27/2023
Jessica Ganga
The FDA’s approval of nalmefene hydrochloride nasal spray marks the first of its kind for health care and community use.
05/27/2023
FDA Alert
fda
FDA Alert
FDA Approves First Prescription Nasal Spray to Reverse Opioid Overdose
05/27/2023
Jessica Ganga
The FDA’s approval of nalmefene hydrochloride nasal spray marks the first of its kind for health care and community use.
05/27/2023
FDA Alert
fda
FDA Alert
FDA Approves First Prescription Nasal Spray to Reverse Opioid Overdose
05/27/2023
Jessica Ganga
The FDA’s approval of nalmefene hydrochloride nasal spray marks the first of its kind for health care and community use.
05/27/2023
FDA alert
fda
FDA alert
First Oral Treatment Approved to Treat Moderate, Severe Crohn Disease
05/25/2023
Jessica Ganga
After clinical trials to assess the safety, efficacy, and maintenance use, the FDA has approved the first oral treatment for moderately to severely active Crohn disease.
05/25/2023
FDA alert
fda
FDA alert
First Oral Treatment Approved to Treat Moderate, Severe Crohn Disease
05/25/2023
Jessica Ganga
After clinical trials to assess the safety, efficacy, and maintenance use, the FDA has approved the first oral treatment for moderately to severely active Crohn disease.
05/25/2023
FDA alert
fda
FDA alert
First Oral Treatment Approved to Treat Moderate, Severe Crohn Disease
05/25/2023
Jessica Ganga
After clinical trials to assess the safety, efficacy, and maintenance use, the FDA has approved the first oral treatment for moderately to severely active Crohn disease.
05/25/2023
FDA alert
fda
FDA alert
First Oral Treatment Approved to Treat Moderate, Severe Crohn Disease
05/25/2023
Jessica Ganga
After clinical trials to assess the safety, efficacy, and maintenance use, the FDA has approved the first oral treatment for moderately to severely active Crohn disease.
05/25/2023
FDA alert
fda
FDA alert
First Oral Treatment Approved to Treat Moderate, Severe Crohn Disease
05/25/2023
Jessica Ganga
After clinical trials to assess the safety, efficacy, and maintenance use, the FDA has approved the first oral treatment for moderately to severely active Crohn disease.
05/25/2023